These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 1513112)

  • 1. Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group.
    Jerums G; Allen TJ; Tsalamandris C; Cooper ME
    Kidney Int; 1992 Apr; 41(4):904-11. PubMed ID: 1513112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of early diabetic nephropathy: what are the effects of therapeutic intervention? Melbourne Diabetic Nephropathy Study Group.
    Jerums G; Allen TJ; Gilbert RE; Hammond J; Cooper ME; Campbell DJ; Raffaele J
    J Diabetes Complications; 1995; 9(4):308-14. PubMed ID: 8573754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of enalapril and nitrendipine on exercise albuminuria in normotensive type I diabetic patients with incipient nephropathy.
    Heinemann L; Janicke I; Bender R; Berger M; Sawicki PT
    Horm Metab Res; 1996 Oct; 28(10):549-52. PubMed ID: 8934214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium antagonists and the diabetic hypertensive patient.
    Parving HH; Rossing P
    Am J Kidney Dis; 1993 Jun; 21(6 Suppl 3):47-52. PubMed ID: 8503435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of beta-blockade and angiotensin converting enzyme inhibition on kidney function in diabetic nephropathy.
    Hommel E
    J Hypertens Suppl; 1989 Sep; 7(7):S49-51. PubMed ID: 2575661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal protection in diabetes--an emerging role for calcium antagonists.
    Parving HH; Tarnow L; Rossing P
    Cardiology; 1997; 88 Suppl 3():56-62. PubMed ID: 9397296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases.
    Mimran A; Ribstein J
    Am J Hypertens; 1994 Sep; 7(9 Pt 2):73S-81S. PubMed ID: 7818839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal protection in diabetes: an emerging role for calcium antagonists.
    Parving HH; Tarnow L; Rossing P
    J Hypertens Suppl; 1996 Nov; 14(4):S21-5. PubMed ID: 8986939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive therapy in patients with diabetic nephropathy.
    Mehler PS; Schrier RW
    Kidney Blood Press Res; 1997; 20(2):74-81. PubMed ID: 9293422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.
    Tarnow L; Rossing P; Jensen C; Hansen BV; Parving HH
    Diabetes Care; 2000 Dec; 23(12):1725-30. PubMed ID: 11128341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy.
    Toto RD; Tian M; Fakouhi K; Champion A; Bacher P
    J Clin Hypertens (Greenwich); 2008 Oct; 10(10):761-9. PubMed ID: 19090877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics.
    BENEDICT Group
    Control Clin Trials; 2003 Aug; 24(4):442-61. PubMed ID: 12865039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.
    Rossing P; Tarnow L; Boelskifte S; Jensen BR; Nielsen FS; Parving HH
    Diabetes; 1997 Mar; 46(3):481-7. PubMed ID: 9032106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
    Rossing K; Christensen PK; Jensen BR; Parving HH
    Diabetes Care; 2002 Jan; 25(1):95-100. PubMed ID: 11772908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials?
    Lasaridis AN; Sarafidis PA
    Am J Hypertens; 2003 Aug; 16(8):689-97. PubMed ID: 12878377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium-channel blockers for treatment of diabetic nephropathy.
    Murray KM
    Clin Pharm; 1991 Nov; 10(11):862-5. PubMed ID: 1794222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
    Katayama S; Yagi S; Yamamoto H; Yamaguchi M; Izumida T; Noguchi Y; Inaba M; Inukai K
    Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria.
    Donnelly R; Molyneaux LM; Willey KA; Yue DK
    Am J Cardiol; 1996 Feb; 77(6):26B-30B. PubMed ID: 8848991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.